Evogene Schedules Third Quarter 2026 Financial Results Release
Evogene (EVGN) will release its financial results for the third quarter of 2026 on November 19, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (EVGN) will release its financial results for the third quarter of 2026 on November 19, 2026. Management will discuss the results on a Zoom conference call that day at 9:00 AM Eastern Time (4:00 PM Israel time). The full conference will be available on the company’s website a few days later.
Details
Market Reaction – EVGN
On Nov 5, the day this news came out, the latest delayed price for EVGN is 12.65% below the previous close. Argus tracked a peak move of +34.1% during the session. Argus tracked a trough of -38.4% from its starting point during tracking. Our momentum scanner has recorded 74 alerts for this stock so far that day. The latest delayed price is $0.29. Relative volume is exceptionally heavy at 236.3x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Zoom conference call scheduled for November 19, 2026, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.
At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Contact:
ir@evogene.com
Tel: +972-8-9311901
View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-schedules-third-quarter-2026-financial-results-release-302930654.html
SOURCE Evogene